查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1854176

2型糖尿病藥物市場按藥物類別、給藥途徑、治療線、分銷管道、品牌類型、患者年齡層和患者性別分類－全球預測（2025-2032年）

Type 2 Diabetes Drugs Market by Drug Class, Route Of Administration, Treatment Line, Distribution Channel, Brand Type, Patient Age Group, Patient Gender - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，2 型糖尿病藥物市場將成長至 1,552 億美元，複合年成長率為 9.14%。

關鍵市場統計數據
基準年 2024 770.7億美元
預計年份：2025年 840.7億美元
預測年份 2032 1552億美元
複合年成長率 (%) 9.14%

對現代第2型糖尿病照護格局進行簡明策略概述，將臨床創新、服務模式和商業性重點連結起來，以引領產業發展。

2型糖尿病是臨床上最複雜、商業性最具活力的治療領域之一，它處於快速治療創新、不斷演變的護理模式以及支付方期望的交匯點。本執行摘要概述了影響產品開發、臨床定位和商業性執行的核心趨勢，涵蓋藥理類別、給藥途徑、治療線、分銷管道和患者群體。其旨在幫助高階領導者將臨床進展和監管趨勢轉化為切實可行的策略重點。

治療方法領域的新進展和綜合護理服務模式的創新再形成糖尿病護理的臨床重點和商業性決策。

2型糖尿病的治療格局正經歷一系列同步轉變，這些轉變正在影響商業性和臨床決策。腸促胰素和鈉-葡萄糖共同輸送體生物學的突破性進展，使得具有多器官效應的藥物數量增加，促使臨床醫生和支付方從更廣泛的心腎代謝角度評估治療方法。因此，處方決策越來越受到真實世界療效以及長期發病率和死亡率數據的影響，而不僅僅是血糖值指標。

評估不斷變化的進口關稅方案將如何影響糖尿病照護價值鏈的供應韌性、採購經濟效益和策略採購決策。

2025年潛在的關稅調整和貿易政策轉變將為製藥企業、經銷商和醫療保健系統帶來新的營運複雜性。原料藥、製劑和給藥裝置的進口關稅提高可能會改變到岸成本，並影響企業在生產區域、庫存緩衝和供應商合約方面的決策。如果關稅造成永久性的成本差異，企業可能會加快近岸外包和雙重籌資策略，以維持供應的連續性和利潤率。

將藥物類別、給藥途徑、治療方案、分銷管道、品牌類型和患者人口統計特徵與策略問題聯繫起來的綜合細分分析

詳細的細分分析揭示了不同藥物類別、給藥方式、治療定位、分銷管道、品牌和患者群體的差異化機會和風險。在各類藥物中，雙胍類藥物由於其製劑層面的差異（例如組合藥物、緩釋性和速釋製劑）而發揮著至關重要的作用，這些差異會影響耐受性和依從性。 DPP-4抑制劑則根據特定的分子實體進行區分，例如阿格列汀、Linagliptin、沙格列汀和sitagliptin，每種藥物都有不同的安全性和交互作用特徵，從而影響處方醫生的偏好。 GLP-1受體促效劑表現出顯著的異質性，例如Dulaglutide、Exenatide、Liraglutide和Semaglutide等藥物，其給藥頻率、減重效果和心血管訊號會影響治療選擇。胰島素製劑分為基礎製劑、Aspart及預混合料製劑三類，其中包括德谷胰島素、地特胰島素及甘精胰島素等基礎製劑；餐前胰島素製劑如門冬胰島素、Glulisine及Lispro；以及預混合料製劑如50/50、70/30及75/25混合製劑。 SGLT2抑制劑包括Canagliflozin、Dapagliflozin、Empagliflozin和厄格列淨，每種藥物的心血管和腎臟結局數據各不相同，這決定了支付方的定價。磺醯尿素類和噻唑烷二酮類藥物，包括氯磺丙脲、Glimepiride、Glipizide、格列PIOGLITAZONE脲、吡格列酮和Rosiglitazone酮，在某些臨床情況下仍然適用，尤其是在成本和已確定的耐受性是關鍵考慮因素時。

世界各主要地區在監管嚴格程度、支付機制和醫療保健基礎設施的區域差異，將影響糖尿病藥物的推廣應用路徑。

區域動態以多種方式影響監管時間表、支付方行為和病患就醫途徑，進而顯著影響臨床應用和商業性執行。在美洲，監管和支付生態系統的特點是私人和公共支付方之間複雜的互動，以及具有心血管代謝獲益的高證據療法的快速普及，這些因素影響著藥品目錄的編入和使用管理。該地區還擁有成熟的專科分銷管道和先進的數位醫療應用，這可以加速患者對注射療法和遠端劑量調整方案的接受度。

公司策略著重於證據生成、夥伴關係和生產韌性，以在糖尿病治療中獲取臨床價值並維持治療生命週期。

領先的製藥和生物技術公司已針對不斷變化的糖尿病市場展現出多種戰略應對措施，包括重點投資GLP-1和SGLT2生物學、擴大胰島素生產能力以及整合藥物-器械-數位化夥伴關係。許多公司正優先考慮血糖終點以外的證據生成，投資於心血管和腎臟結局研究、真實世界證據項目以及衛生經濟學模型，以支持與支付方進行基於價值的合約談判。在公司層面，生命週期管理策略強調新製劑、給藥裝置創新和適應症拓展，以維持臨床相關性並延長產品壽命。

為加速以病人為中心的治療方法的推廣，同時協調實證醫學的產生、醫療資源的保障和支付方的參與，領導階層需要採取切實可行的策略要務。

產業領導者應採取多管齊下的策略，協調臨床差異化、供應可靠性和支付方參與，以維持藥物可及性和商業性績效。首先，優先創建可靠的真實世界證據和結果數據，將治療藥物與降低心血管和腎臟事件發生率聯繫起來。其次，多元化籌資策略，加速區域生產，以降低關稅和供應鏈風險，同時保持利潤彈性和病患可及性。第三，投資於給藥平台創新，例如長效製劑和易於使用的注射器，並結合能夠證明其持久性和改善健康結果的數位依從性解決方案。

調查方法框架結合了主要相關人員訪談、嚴格的二手證據綜合和可靠的三角測量，以確保可操作的資訊和分析的嚴謹性。

本執行摘要依據的分析整合了多項定性和定量研究，以確保得出可靠且可操作的結論。主要研究包括對臨床醫生、支付方代表、藥房負責人和行業高管進行深度訪談，以了解處方行為、報銷促進因素和供應鏈限制等方面的實際觀點。次要研究包括對同行評審的臨床試驗、監管申報文件、經裁定的結果研究和指南更新進行系統性回顧，以檢驗治療定位和安全性訊號。

將臨床創新、支付方動態和營運韌性進行綜合分析，以指南糖尿病照護生命週期中的策略決策。

整體而言，第2型糖尿病領域呈現出臨床創新加速、支付方預期不斷變化以及營運壓力日益增大的特點，這些都需要採取全面性的策略應對措施。治療藥物，尤其是那些具有良好心血管和腎臟安全性的藥物，正在重塑臨床模式，而給藥方式的創新和數位化支持正在重新定義治療依從性和連續性。同時，貿易政策的動態和供應鏈的脆弱性要求採取積極的採購和生產策略，以維持藥物的可及性和競爭力。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • GIP/GLP-1促效劑的雙重激動劑已顯示出優異的血糖控制和減重效果，因此越來越受到關注。
  • 除了血糖控制外，SGLT2抑制劑在心血管和腎臟保護方面的應用日益廣泛。
  • 隨著人工智慧指導的胰島素劑量調整和持續血糖監測的融合，個人化糖尿病管理模式正在興起。
  • 口服Semaglutide越來越受到關注，它能提高第 2 型糖尿病患者的便利性和依從性。
  • 監管部門核准每週一次基礎胰島素類似物，以改善空腹血糖值穩定性並提高患者便利性
  • 開發葡萄糖響應型胰島素技術，以降低低血糖風險並提高生活品質

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 2型糖尿病藥物市場（依藥物類別分類）

  • 比瓜尼德斯
    • 複方製劑
    • 加長版
    • 即時發布
  • DPP-4抑制劑
    • 阿格列汀
    • Linagliptin
    • 沙格列汀
    • sitagliptin
  • GLP-1受體促效劑
    • Dulaglutide
    • Exenatide
    • Liraglutide
    • Semaglutide
  • 胰島素
    • 基礎藥物
      • 德谷
      • 德特米爾
      • 甘精
    • 普蘭迪亞爾
      • Aspart
      • Glulisine
      • Lispro
    • 預混合料配方
      • 50/50混合物
      • 70/30 混合
      • 75/25 混合
  • SGLT2抑制劑
    • Canagliflozin
    • Dapagliflozin
    • Empagliflozin
    • 艾格列淨
  • 磺醯尿素類
    • 氯丙醯胺
    • Glimepiride
    • Glipizide
    • 格列本脲
  • 噻唑烷二酮
    • PIOGLITAZONE
    • Rosiglitazone

9. 依給藥途徑分類的第2型糖尿病藥物市場

  • 注射
    • 筆
    • 預填充式注射器
  • 口服
    • 膠囊
    • 藥片

第10章 依治療類別分類的第二型糖尿病藥物市場

  • 第一選擇
    • 組合
      • 雙重療法
      • 三聯療法
    • 單藥治療
  • 第二選擇
  • 第三選擇

第11章 依分銷管道分類的2型糖尿病藥物市場

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章：依品牌類型分類的第二型糖尿病藥物市場

  • 原廠產品
  • 非專利的

第13章：依患者年齡層分類的第2型糖尿病藥物市場

  • 18至65歲
  • 65歲或以上

第14章 依患者性別分類的第二型糖尿病藥物市場

  • 女士
  • 男性

第15章 各地區第二型糖尿病藥物市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章：按組別分類的第2型糖尿病藥物市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章 各國第二型糖尿病藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Novo Nordisk A/S
    • Eli Lilly and Company
    • Sanofi SA
    • Merck & Co., Inc.
    • AstraZeneca PLC
    • Boehringer Ingelheim International GmbH
    • Johnson & Johnson
    • Pfizer Inc.
    • Novartis AG
    • Daiichi Sankyo Company, Limited
Product Code: MRR-7162E4C3E9C3

The Type 2 Diabetes Drugs Market is projected to grow by USD 155.20 billion at a CAGR of 9.14% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 77.07 billion
Estimated Year [2025] USD 84.07 billion
Forecast Year [2032] USD 155.20 billion
CAGR (%) 9.14%

Concise strategic overview of the contemporary type 2 diabetes therapeutic environment linking clinical innovation, delivery models, and commercial priorities for leadership

Type 2 diabetes remains among the most clinically complex and commercially dynamic therapeutic areas, with rapid therapeutic innovation intersecting with evolving care models and payer expectations. This executive summary synthesizes core trends shaping product development, clinical positioning, and commercial execution across pharmacological classes, routes of administration, treatment lines, distribution channels, and patient demographics. It is structured to help senior leaders translate clinical progress and regulatory developments into pragmatic strategic priorities.

Across treatment modalities, the landscape is being reshaped by agents that extend beyond glycemic control to address cardiovascular, renal, and weight-related outcomes. At the same time, digitization of care pathways, patient-centric adherence solutions, and evolving reimbursement frameworks are redefining how therapies are adopted and utilized. Stakeholders must balance innovation with access considerations to sustain long-term patient benefit while preserving commercial viability. The following sections unpack transformative shifts, regulatory and trade-related headwinds, segmentation-level insights, regional nuances, corporate strategies, and tactical recommendations to guide leadership decision-making. Each section integrates current clinical and commercial intelligence and highlights implications for portfolio management, supply chain strategy, and stakeholder engagement.

Emerging therapeutic advances and integrated care delivery innovations are reshaping clinical priorities and reshuffling commercial decision levers in diabetes care

The therapeutic landscape for type 2 diabetes is experiencing a set of concurrent, reinforcing shifts that collectively reorient commercial and clinical decision-making. Breakthroughs in incretin and sodium-glucose cotransporter biology have elevated agents with multi-system benefits, prompting clinicians and payers to assess therapies through a broader cardiorenal-metabolic lens. As a consequence, formulary decisions are increasingly influenced by real-world outcomes and long-term morbidity and mortality data rather than immediate glycemic metrics alone.

Simultaneously, the rapid acceptance of long-acting injectable and novel oral formulations has expanded patient choice, necessitating nuanced positioning strategies that align administration mode with adherence patterns and patient preference. Digital therapeutics and remote monitoring are moving from pilot projects toward integrated disease-management solutions, enabling longitudinal adherence support and more granular value demonstration to payers. Parallel to these clinical and technological shifts, competitive dynamics are being reshaped by lifecycle management, biosimilar emergence, and cross-sector partnerships that combine pharmaceutical expertise with devices, diagnostics, and software. Together, these forces are accelerating demand for differentiated evidence generation, adaptive pricing strategies, and targeted provider engagement to realize both clinical benefit and commercial success.

Assessing how evolving import tariff scenarios could alter supply resilience, procurement economics, and strategic sourcing decisions across the diabetes therapeutic value chain

Potential tariff changes and trade policy shifts in 2025 introduce an added dimension of operational complexity for pharmaceutical manufacturers, distributors, and health systems. Increased import duties on active pharmaceutical ingredients, finished formulations, or delivery devices can alter landed costs and influence decisions about production geography, inventory buffers, and supplier contracts. Where tariffs create persistent cost differentials, firms are likely to accelerate nearshoring and dual-sourcing strategies to preserve continuity of supply and margin integrity.

Beyond unit cost implications, tariff-driven supply chain adjustments can elongate lead times and raise the operational premium on quality control and regulatory harmonization across jurisdictions. Payers and integrated delivery networks may respond to higher procurement costs by intensifying formulary management, seeking therapeutic substitutions where clinically appropriate, or renegotiating procurement contracts with manufacturers. For manufacturers, this environment increases the importance of transparent cost-of-goods analysis, scenario planning, and proactive engagement with payers to articulate value propositions tied to long-term health outcomes.

Finally, tariff pressures can intensify collaboration between pharmaceutical companies and contract manufacturers to localize critical production steps, while also amplifying investments in manufacturing efficiency and biologics capacity. For product teams, understanding the interplay between trade policy, supply resilience, and pricing dynamics will be essential for preserving patient access and sustaining lifecycle strategies in the coming years.

Comprehensive segmentation analysis linking drug classes, administration routes, treatment lines, distribution channels, brand typologies, and patient demographics to strategic imperatives

Granular segmentation reveals differentiated opportunities and risks across therapeutic classes, modes of delivery, treatment positioning, channels of distribution, brand status, and patient demographics. Within drug classes, biguanides maintain a foundational role with formulation-level differentiation across combination formulations, extended release, and immediate release options that affect tolerability and adherence profiles. DPP-4 inhibitors differentiate by specific molecular entities such as alogliptin, linagliptin, saxagliptin, and sitagliptin, each presenting distinct safety and interaction profiles that inform prescriber preference. GLP-1 receptor agonists show pronounced heterogeneity driven by agents such as dulaglutide, exenatide, liraglutide, and semaglutide, where dosing frequency, weight-loss effects, and cardiovascular signals influence therapeutic selection. Insulin products are stratified into basal, prandial, and premixed categories, with basal options like degludec, detemir, and glargine, prandial options like aspart, glulisine, and lispro, and premixed formulations spanning 50/50, 70/30, and 75/25 mixes; each subgroup has implications for titration complexity and delivery device compatibility. SGLT2 inhibitors comprise agents such as canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin, each with distinct cardiovascular and renal outcome data that shape payer positioning. Sulfonylureas and thiazolidinediones, with constituents like chlorpropamide, glimepiride, glipizide, glyburide, pioglitazone, and rosiglitazone, remain relevant in specific clinical contexts, especially where cost and established tolerability profiles are primary considerations.

Route of administration segmentation distinguishes injectable formats, including pen and prefilled syringe devices, from oral capsules and tablets, and this division materially affects adherence, patient education needs, and device-related supply chain considerations. Treatment line segmentation-first line, second line, and third line-requires careful mapping of combination versus monotherapy strategies, where first-line combination approaches further bifurcate into dual and triple therapy regimens, each presenting unique evidence generation and payer negotiation requirements. Distribution channel dynamics across hospital pharmacy, online pharmacy, and retail pharmacy influence stocking practices, cold chain obligations, and point-of-care education, while brand type segmentation between branded and generic products drives differential pricing, promotion, and lifecycle tactics. Patient demographics such as age cohorts (18 to 65 and above 65) and gender differences (female and male) call for tailored adherence programs, comorbidity-aware treatment selection, and communications calibrated to differing risk profiles and healthcare utilization patterns. Integrating these segmentation layers enables more precise targeting of clinical development, commercial deployment, and outcomes measurement across the full product lifecycle.

Regional variations in regulatory rigor, payer mechanisms, and healthcare infrastructure shape differentiated adoption pathways for diabetes therapies across major global regions

Regional dynamics influence regulatory timelines, payer behavior, and patient access in ways that materially affect clinical adoption and commercial execution. In the Americas, regulatory and payer ecosystems are characterized by rapid uptake of high-evidence therapies that demonstrate cardiorenal-metabolic benefits, alongside a complex interplay between private insurers and public payers that shapes formulary positioning and utilization management. This region also features mature specialty distribution channels and advanced digital health adoption, which can accelerate patient onboarding to injectable therapies and remote titration programs.

The Europe, Middle East & Africa region presents pronounced heterogeneity; western European markets often prioritize robust health economic evidence and health-technology assessments when evaluating new therapies, requiring rich real-world data and cost-effectiveness analyses. Middle Eastern markets frequently focus on expedited access and volume-based procurement models, while African markets face infrastructure constraints and affordability barriers that influence therapy selection and distribution strategies. Navigating this regional mosaic requires tailored regulatory engagement plans and adaptable commercial models that respect local procurement mechanisms and reimbursement pathways.

Asia-Pacific exhibits diverse therapeutic trajectories, with some markets adopting novel agents rapidly due to growing cardiometabolic disease burden and strong primary care networks, while others emphasize local manufacturing and generic substitution to manage costs. In several countries, government-driven initiatives to strengthen diabetes screening and chronic disease management are expanding care pathways, creating opportunities for integrated therapeutic and digital solutions. Across all regions, regional supply chain optimization, evidence localization, and culturally sensitive patient support programs are critical to converting clinical innovation into sustainable patient access.

Corporate strategies converge on evidence generation, partnerships, and manufacturing resilience to capture clinical value and sustain therapeutic lifecycles in diabetes care

Leading pharmaceutical and biotech companies demonstrate a spectrum of strategic responses to the evolving diabetes landscape, including focused investments in GLP-1 and SGLT2 biology, expansion of insulin manufacturing capacity, and partnerships that integrate drug, device, and digital engagement. Many organizations are prioritizing evidence generation beyond glycemic endpoints by investing in cardiovascular and renal outcomes studies, real-world evidence programs, and health-economic modeling to support value-based contracting discussions with payers. At the corporate level, lifecycle management strategies emphasize new formulations, delivery device innovation, and indication expansion to sustain clinical relevance and extend product longevity.

Strategic alliances between established manufacturers and emerging biotech firms are accelerating the translation of novel mechanisms and combination approaches into clinical development. Contract manufacturing and specialized API partnerships are being used to mitigate capacity constraints and diversify supply bases. Companies are also investing in omnichannel commercial models that combine provider education, digital patient support, and targeted field force engagement to improve persistence and adherence. Finally, corporate strategies are increasingly incorporating sustainability and manufacturing resilience objectives to address environmental, social, and governance expectations while reducing operational risk.

Actionable strategic imperatives for leadership to align evidence generation, supply resilience, and payer engagement while accelerating patient-centric adoption of therapies

Industry leaders should adopt a multi-pronged approach that aligns clinical differentiation, supply reliability, and payer engagement to sustain access and commercial performance. First, prioritize generation of robust real-world evidence and outcomes data that link therapies to reductions in cardiovascular and renal events, as this will materially strengthen conversations with payers and integrated health systems. Second, diversify sourcing strategies and accelerate regional manufacturing options to mitigate tariff and supply-chain risk while preserving margin flexibility and patient access. Third, invest in delivery-platform innovation, including long-acting formulations and user-friendly injection devices, paired with digital adherence solutions that demonstrate improvements in persistence and health outcomes.

Additionally, pursue value-based contracting pilots with performance-based reimbursement linked to meaningful clinical endpoints, and tailor these agreements to regional payer expectations and regulatory realities. Optimize channel strategies by strengthening partnerships with hospital pharmacies for acute care settings, online pharmacies for chronic care continuity, and retail partners for community-level access and education. Develop differentiated lifecycle plans that include strategic sequencing of branded innovations and planned generic transitions, accompanied by targeted communication strategies for vulnerable age cohorts and gender-specific adherence interventions. Finally, embed sustainability and quality-by-design principles into operational planning to enhance long-term resilience and stakeholder trust.

Methodological framework combining primary stakeholder interviews, rigorous secondary evidence synthesis, and robust triangulation to ensure actionable intelligence and analytical rigor

The analysis underpinning this executive summary synthesizes multiple qualitative and quantitative research streams to ensure robust and actionable insights. Primary research included in-depth interviews with clinicians, payer representatives, pharmacy leaders, and industry executives to capture frontline perspectives on prescribing behavior, reimbursement drivers, and supply-chain constraints. Secondary research involved a systematic review of peer-reviewed clinical trials, regulatory filings, adjudicated outcomes studies, and guideline updates to verify therapeutic positioning and safety signals.

Data triangulation methods were applied to reconcile insights across sources, with particular emphasis on aligning clinical trial evidence with real-world utilization patterns observed in claims and electronic health record studies. Segmentation mapping incorporated drug class, route of administration, treatment line, distribution channel, brand type, and patient demographics to produce a multidimensional view of adoption dynamics. Quality assurance processes included expert validation sessions and methodological audits to ensure analytical rigor. Limitations are acknowledged where public data are sparse or where evolving regulatory decisions may alter therapeutic trajectories; nevertheless, the methodological framework provides a defensible basis for strategic planning and operational decision-making.

Integrated synthesis of clinical innovation, payer dynamics, and operational resilience to guide strategic decision-making across the diabetes therapy lifecycle

In aggregate, the type 2 diabetes landscape is characterized by accelerating clinical innovation, shifting payer expectations, and operational pressures that together demand integrated strategic responses. Therapies that demonstrate multi-system benefits-particularly those with favorable cardiovascular and renal profiles-are reshaping clinical paradigms, while delivery-mode innovation and digital support are redefining adherence and care continuity. At the same time, trade policy dynamics and supply-chain vulnerabilities require proactive sourcing and manufacturing strategies to maintain access and competitiveness.

Leaders who align evidence generation with pragmatic commercialization tactics, invest in resilient supply chains, and engage payers with outcomes-focused propositions will be best positioned to translate therapeutic advances into sustained patient benefit and organizational value. The insights in this executive summary are designed to inform cross-functional decision-making across clinical development, commercial strategy, supply chain, and policy engagement to navigate near-term disruptions and capture long-term opportunities in diabetes care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising prominence of dual GIP/GLP-1 receptor agonists demonstrating superior glycemic control and weight loss
  • 5.2. Increased adoption of SGLT2 inhibitors for cardiovascular and renal protection beyond glycemic management
  • 5.3. Emergence of personalized diabetes management through continuous glucose monitoring integrated with AI-driven insulin dosing
  • 5.4. Growing focus on oral semaglutide formulations to enhance patient convenience and adherence in type 2 diabetes
  • 5.5. Regulatory approvals for once-weekly basal insulin analogs offering improved fasting glucose stability and patient convenience
  • 5.6. Development of glucose-responsive insulin technologies aimed at reducing hypoglycemia risk and improving quality of life

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Type 2 Diabetes Drugs Market, by Drug Class

  • 8.1. Biguanides
    • 8.1.1. Combination Formulations
    • 8.1.2. Extended Release
    • 8.1.3. Immediate Release
  • 8.2. DPP-4 Inhibitors
    • 8.2.1. Alogliptin
    • 8.2.2. Linagliptin
    • 8.2.3. Saxagliptin
    • 8.2.4. Sitagliptin
  • 8.3. GLP-1 Receptor Agonists
    • 8.3.1. Dulaglutide
    • 8.3.2. Exenatide
    • 8.3.3. Liraglutide
    • 8.3.4. Semaglutide
  • 8.4. Insulin
    • 8.4.1. Basal
      • 8.4.1.1. Degludec
      • 8.4.1.2. Detemir
      • 8.4.1.3. Glargine
    • 8.4.2. Prandial
      • 8.4.2.1. Aspart
      • 8.4.2.2. Glulisine
      • 8.4.2.3. Lispro
    • 8.4.3. Premixed
      • 8.4.3.1. 50/50 Mix
      • 8.4.3.2. 70/30 Mix
      • 8.4.3.3. 75/25 Mix
  • 8.5. SGLT2 Inhibitors
    • 8.5.1. Canagliflozin
    • 8.5.2. Dapagliflozin
    • 8.5.3. Empagliflozin
    • 8.5.4. Ertugliflozin
  • 8.6. Sulfonylureas
    • 8.6.1. Chlorpropamide
    • 8.6.2. Glimepiride
    • 8.6.3. Glipizide
    • 8.6.4. Glyburide
  • 8.7. Thiazolidinediones
    • 8.7.1. Pioglitazone
    • 8.7.2. Rosiglitazone

9. Type 2 Diabetes Drugs Market, by Route Of Administration

  • 9.1. Injectable
    • 9.1.1. Pen
    • 9.1.2. PreFilled Syringe
  • 9.2. Oral
    • 9.2.1. Capsule
    • 9.2.2. Tablet

10. Type 2 Diabetes Drugs Market, by Treatment Line

  • 10.1. First Line
    • 10.1.1. Combination
      • 10.1.1.1. Dual Therapy
      • 10.1.1.2. Triple Therapy
    • 10.1.2. Monotherapy
  • 10.2. Second Line
  • 10.3. Third Line

11. Type 2 Diabetes Drugs Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Type 2 Diabetes Drugs Market, by Brand Type

  • 12.1. Branded
  • 12.2. Generic

13. Type 2 Diabetes Drugs Market, by Patient Age Group

  • 13.1. 18 To 65
  • 13.2. Above 65

14. Type 2 Diabetes Drugs Market, by Patient Gender

  • 14.1. Female
  • 14.2. Male

15. Type 2 Diabetes Drugs Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Type 2 Diabetes Drugs Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Type 2 Diabetes Drugs Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. Competitive Landscape

  • 18.1. Market Share Analysis, 2024
  • 18.2. FPNV Positioning Matrix, 2024
  • 18.3. Competitive Analysis
    • 18.3.1. Novo Nordisk A/S
    • 18.3.2. Eli Lilly and Company
    • 18.3.3. Sanofi S.A.
    • 18.3.4. Merck & Co., Inc.
    • 18.3.5. AstraZeneca PLC
    • 18.3.6. Boehringer Ingelheim International GmbH
    • 18.3.7. Johnson & Johnson
    • 18.3.8. Pfizer Inc.
    • 18.3.9. Novartis AG
    • 18.3.10. Daiichi Sankyo Company, Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY TREATMENT LINE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY TREATMENT LINE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BRAND TYPE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BRAND TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT GENDER, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT GENDER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. NORTH AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. LATIN AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. EUROPE TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. MIDDLE EAST TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. ASEAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GCC TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. EUROPEAN UNION TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BRICS TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. G7 TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. NATO TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. TYPE 2 DIABETES DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 34. TYPE 2 DIABETES DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. TYPE 2 DIABETES DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION FORMULATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION FORMULATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION FORMULATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION FORMULATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION FORMULATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION FORMULATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ALOGLIPTIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ALOGLIPTIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ALOGLIPTIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ALOGLIPTIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ALOGLIPTIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ALOGLIPTIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY LINAGLIPTIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY LINAGLIPTIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY LINAGLIPTIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY LINAGLIPTIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY LINAGLIPTIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY LINAGLIPTIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SAXAGLIPTIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SAXAGLIPTIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SAXAGLIPTIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SAXAGLIPTIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SAXAGLIPTIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SAXAGLIPTIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SITAGLIPTIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SITAGLIPTIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SITAGLIPTIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SITAGLIPTIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SITAGLIPTIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SITAGLIPTIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DULAGLUTIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DULAGLUTIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DULAGLUTIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DULAGLUTIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DULAGLUTIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DULAGLUTIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY EXENATIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY EXENATIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY EXENATIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY EXENATIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY EXENATIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY EXENATIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY LIRAGLUTIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY LIRAGLUTIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY LIRAGLUTIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY LIRAGLUTIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY LIRAGLUTIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY LIRAGLUTIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SEMAGLUTIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SEMAGLUTIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SEMAGLUTIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SEMAGLUTIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SEMAGLUTIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SEMAGLUTIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INSULIN, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INSULIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INSULIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INSULIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INSULIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INSULIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INSULIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BASAL, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BASAL, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BASAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BASAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BASAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BASAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BASAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BASAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DEGLUDEC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DEGLUDEC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DEGLUDEC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DEGLUDEC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DEGLUDEC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DEGLUDEC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DETEMIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DETEMIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DETEMIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DETEMIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DETEMIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DETEMIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLARGINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLARGINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLARGINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLARGINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLARGINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLARGINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRANDIAL, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRANDIAL, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRANDIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRANDIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRANDIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRANDIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRANDIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRANDIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ASPART, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ASPART, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ASPART, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ASPART, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ASPART, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ASPART, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLULISINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLULISINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLULISINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLULISINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLULISINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLULISINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY LISPRO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY LISPRO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY LISPRO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY LISPRO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY LISPRO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY LISPRO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREMIXED, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREMIXED, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREMIXED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREMIXED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREMIXED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREMIXED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREMIXED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREMIXED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 50/50 MIX, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 50/50 MIX, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 50/50 MIX, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 50/50 MIX, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 50/50 MIX, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 50/50 MIX, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 70/30 MIX, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 70/30 MIX, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 70/30 MIX, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 70/30 MIX, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 70/30 MIX, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 70/30 MIX, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 75/25 MIX, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 75/25 MIX, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 75/25 MIX, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 75/25 MIX, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 75/25 MIX, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 75/25 MIX, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CANAGLIFLOZIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CANAGLIFLOZIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CANAGLIFLOZIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CANAGLIFLOZIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CANAGLIFLOZIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CANAGLIFLOZIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DAPAGLIFLOZIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DAPAGLIFLOZIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DAPAGLIFLOZIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DAPAGLIFLOZIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DAPAGLIFLOZIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DAPAGLIFLOZIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY EMPAGLIFLOZIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY EMPAGLIFLOZIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY EMPAGLIFLOZIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY EMPAGLIFLOZIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY EMPAGLIFLOZIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY EMPAGLIFLOZIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ERTUGLIFLOZIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ERTUGLIFLOZIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ERTUGLIFLOZIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ERTUGLIFLOZIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ERTUGLIFLOZIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ERTUGLIFLOZIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CHLORPROPAMIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CHLORPROPAMIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CHLORPROPAMIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CHLORPROPAMIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CHLORPROPAMIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CHLORPROPAMIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLIMEPIRIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLIMEPIRIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLIMEPIRIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLIMEPIRIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLIMEPIRIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLIMEPIRIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLIPIZIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLIPIZIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLIPIZIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLIPIZIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLIPIZIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLIPIZIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLYBURIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLYBURIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLYBURIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLYBURIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLYBURIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLYBURIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PIOGLITAZONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PIOGLITAZONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PIOGLITAZONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PIOGLITAZONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PIOGLITAZONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PIOGLITAZONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ROSIGLITAZONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ROSIGLITAZONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ROSIGLITAZONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ROSIGLITAZONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ROSIGLITAZONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ROSIGLITAZONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREFILLED SYRINGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREFILLED SYRINGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREFILLED SYRINGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREFILLED SYRINGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 301. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 302. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 303. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 304. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 305. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 306. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 307. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 308. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 309. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
  • TABLE 310. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY TREATMENT LINE, 2025-2032 (USD MILLION)
  • TABLE 311. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY FIRST LINE, 2018-2024 (USD MILLION)
  • TABLE 312. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY FIRST LINE, 2025-2032 (USD MILLION)
  • TABLE 313. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 314. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 315. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 316. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY FIRST LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 317. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 318. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 319. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION, 2018-2024 (USD MILLION)
  • TABLE 320. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION, 2025-2032 (USD MILLION)
  • TABLE 321. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION, BY REGION, 2018-202